Sweden · Delayed Price · Currency is SEK Dicot Pharma AB Statistics
Total Valuation
Dicot Pharma AB has a market cap or net worth of SEK 1.07 billion. The enterprise value is 1.06 billion.
| Market Cap | 1.07B |
| Enterprise Value | 1.06B |
Important Dates
The next estimated earnings date is Wednesday, February 18, 2026.
| Earnings Date | Feb 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Dicot Pharma AB has 2.01 billion shares outstanding. The number of shares has increased by 126.82% in one year.
| Current Share Class | 2.01B |
| Shares Outstanding | 2.01B |
| Shares Change (YoY) | +126.82% |
| Shares Change (QoQ) | +1.36% |
| Owned by Insiders (%) | 9.33% |
| Owned by Institutions (%) | 12.86% |
| Float | 1.74B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 11.88 |
| P/TBV Ratio | 76.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.59 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.52
| Current Ratio | 9.52 |
| Quick Ratio | 8.82 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8,697.90 |
Financial Efficiency
Return on equity (ROE) is -75.52% and return on invested capital (ROIC) is -48.82%.
| Return on Equity (ROE) | -75.52% |
| Return on Assets (ROA) | -44.98% |
| Return on Invested Capital (ROIC) | -48.82% |
| Return on Capital Employed (ROCE) | -96.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -21.02M |
| Employee Count | 3 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +167.00% in the last 52 weeks. The beta is 1.61, so Dicot Pharma AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.61 |
| 52-Week Price Change | +167.00% |
| 50-Day Moving Average | 0.84 |
| 200-Day Moving Average | 0.54 |
| Relative Strength Index (RSI) | 38.31 |
| Average Volume (20 Days) | 71,588,440 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -86.98M |
| Pretax Income | -84.10M |
| Net Income | -84.10M |
| EBITDA | -86.97M |
| EBIT | -86.98M |
| Earnings Per Share (EPS) | -0.05 |
Balance Sheet
The company has 90.00 million in cash and n/a in debt, giving a net cash position of 90.00 million or 0.04 per share.
| Cash & Cash Equivalents | 90.00M |
| Total Debt | n/a |
| Net Cash | 90.00M |
| Net Cash Per Share | 0.04 |
| Equity (Book Value) | 90.30M |
| Book Value Per Share | 0.01 |
| Working Capital | 90.30M |
Cash Flow
| Operating Cash Flow | -82.47M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Dicot Pharma AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -126.82% |
| Shareholder Yield | -126.82% |
| Earnings Yield | -7.84% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |